AL-LAD

AL-LAD, also known as 6-allyl-6-nor-LSD, is a psychedelic drug and an analog of lysergic acid diethylamide (LSD). It is known for its psychedelic effects similar to LSD, though users report that it has a somewhat different psychopharmacological profile, often described as being less intense and having a shorter duration of action.
Chemistry[edit]
AL-LAD is a structural analog of LSD, with the difference being the substitution of an allyl group for the methyl group at the nitrogen atom of the polycyclic indole group of LSD. Its chemical name is (6aR,9R)-N-allyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide. Like LSD, AL-LAD acts as a partial agonist at the 5-HT2A receptor. However, the exact nature of its psychoactive effects and pharmacological profile is less well-understood due to its relatively recent emergence on the research chemical market.
History[edit]
AL-LAD was first synthesized by David E. Nichols as part of a research project on LSD analogs. However, it did not gain significant attention until it appeared on the recreational drug market in the early 2010s. Since then, it has been sold as a legal alternative to LSD in countries where it is not specifically controlled.
Effects[edit]
The effects of AL-LAD are reported to be similar to those of LSD, including visual hallucinations, altered thinking processes, an altered sense of time, and spiritual experiences. However, users often report that AL-LAD is somewhat less potent than LSD, with a shorter duration of effects—typically lasting 6 to 8 hours, compared to the 8 to 12 hours or more of LSD. The subjective effects of AL-LAD can vary greatly depending on the dose, the individual's psychology, and the environment in which it is used.
Legality[edit]
The legal status of AL-LAD varies by country. In some places, it is not specifically listed as a controlled substance but may be considered illegal under analog laws that ban chemicals similar to prohibited substances. In other jurisdictions, AL-LAD has been explicitly banned and is treated similarly to other controlled psychedelic substances.
Safety[edit]
As with other psychedelic substances, the safety profile of AL-LAD is not fully understood. It is considered to have a low toxicity relative to dose, but as with all psychedelics, it can produce strong psychological effects that may be challenging or distressing. There is limited data on the long-term effects of AL-LAD use, and it should be approached with caution, especially by individuals with a history of mental health issues.
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
